EEG Study on Neurophysiological and Psychological Effects of Ericksonian Hypnotherapy in Generalized Anxiety Disorder

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUskudar University

About this trial

This study examines the neurophysiological and psychological effects of Ericksonian hypnotherapy in individuals diagnosed with Generalized Anxiety Disorder (GAD). Using electroencephalography (EEG), the study aims to assess changes in brain activity and anxiety symptoms before and after treatment.

A total of 60 participants will be recruited from both governmental and private psychiatric clinics in Istanbul. Participants will be randomly assigned to either the intervention group (receiving 12 Ericksonian hypnotherapy sessions over 12 weeks) or the control group (receiving no intervention).

The primary outcome measures include changes in EEG patterns, specifically alpha, theta, and frontal asymmetry indices, and changes in anxiety severity, measured by the Beck Anxiety Inventory (BAI), Generalized Anxiety Disorder-7 (GAD-7), and State-Trait Anxiety Inventory (STAI). Secondary measures include emotional regulation (DERS) and quality of life (WHOQOL-BREF).

This study aims to provide scientific evidence on the effectiveness of Ericksonian hypnotherapy as a complementary treatment for GAD and its impact on brain function and emotional well-being.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of Generalized Anxiety Disorder (GAD) based on DSM-5 criteria

Aged 18-65 years

Capable of providing written informed consent

Fluent in Turkish (for hypnosis and assessments)

Disqualifiers

Presence of comorbid psychiatric disorders (e.g., schizophrenia, bipolar disorder, major depression requiring immediate intervention)

History of neurological conditions (e.g., epilepsy, traumatic brain injury, stroke)

Current use of medications affecting EEG activity (e.g., benzodiazepines, SSRIs, antipsychotics)

Previous experience with hypnotherapy (to avoid expectancy bias)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Ericksonian Hypnotherapy

    Behavioral

    Ericksonian hypnotherapy is a therapeutic approach that utilizes indirect suggestion, storytelling, and metaphorical language to induce a trance state and facilitate psychological change. This intervention aims to reduce anxiety symptoms, improve emotional regulation, and alter neurophysiological responses as measured by EEG. Participants will undergo 12 individual sessions, each lasting 90 minutes, over a period of 12 weeks.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Ericksonian Hypnotherapy GroupExperimental treatment 1 intervention
Group B: Control GroupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

EEG Changes in Brain Activity

Measure: Changes in alpha, theta power, and frontal asymmetry indices before and after intervention Description: EEG will be used to assess changes in resting-state brain activity and event-related potentials (ERPs: P300, N200), evaluating neurophysiological effects of Ericksonian hypnotherapy.

Time frame
Baseline (Pre-intervention) and Post-intervention (12 weeks)
2

Beck Anxiety Inventory (BAI)

Change in BAI scores (0-63, higher scores indicate more severe anxiety).

Time frame
Baseline and Post-intervention (12 weeks)

Secondary outcomes

1

Generalized Anxiety Severity (Generalized Anxiety Disorder-7, GAD-7)

Change in GAD-7 scores (0-21, higher scores indicate more severe anxiety)

Time frame
Baseline and Post-intervention (12 weeks)
2

State and Trait Anxiety Levels (State-Trait Anxiety Inventory, STAI)

Change in STAI scores (20-80, higher scores indicate greater anxiety).

Time frame
Baseline and Post-intervention (12 weeks)
3

Difficulties in Emotion Regulation Scale, (DERS)

Change in DERS scores (36-180, higher scores indicate greater emotion regulation difficulties).

Time frame
Baseline and Post-intervention (12 weeks)
4

World Health Organization Quality of Life Scale, (WHOQOL-BREF)

Change in WHOQOL-BREF scores (0-100, higher scores indicate better quality of life).

Time frame
Baseline and Post-intervention (12 weeks)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Uskudar University

Lead sponsor

Istanbul Nisantasi University

Collaborator

Beykoz University

Collaborator